GSK shares leap 5% as results top forecasts and guidance is upgraded! Can they keep rising?

Strong full-year trading and an improving outlook have propelled GSK’s share price higher, as Royston Wild explains.

| More on:
Man smiling and working on laptop

Image source: Getty images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK (LSE:GSK) shares ended 2024 on a sour note after what proved to be a rollercoaster year.

The pharma giant dropped 7% over the 12 months, as worries over Zantac litigation and potential shake-ups in US healthcare policy shook investor confidence.

Yet the underlying health of the FTSE 100 firm has remained steadfast, as illustrated by impressive full-year results released today (5 February).

GSK’s share price has spiked 5% following the news. Can it keep going?

Forecasts beaten

Helped by what it described as “accelerating momentum in Specialty Medicines“, full-year revenues at GSK rose 7% at constant currencies to £31.4bn. This beat broker consensus estimates by around £300m.

Turnover was up 4% at actual exchange rates.

GSK said that “continued growth across disease areas” pushed Specialty Medicine sales 19% higher at stable currencies, to £11.8bn. Oncology was the standout here, with revenues almost doubling year on year on the same basis (up 98%).

Strength here more than offset a 4% sales decline at the firm’s Vaccines division. Turnover dropped as stricter age rules in the US for respiratory syncytial virus (RSV) treatment caused Arexvy sales to plummet 51%.

At group level, GSK’s operating profit dropped 33% and 40% at actual and constant currencies, respectively, to £4bn. It reflected a £1.8bn charge as the business settled US claims that its Zantac heartburn drug caused cancer.

Core operating profit, which strips out these litigatory headwinds, rose 11% from 2023 levels.

Strong momentum

GSK’s on a roll at the moment. Following a series of guidance upgrades last year, it’s got 2025 off to a bang and is expecting another year of solid progress.

The Footsie firm expects turnover to rise between 3% and 5% at constant currencies, and core operating profit to advance between 6% and 8%.

GSK also hiked its 2031 sales target, which it said reflected “late-stage pipeline progress”. Turnover is now tipped at £40bn, a £2bn upgrade from prior targets.

Today, the company has 71 Specialty Medicines and Vaccines in clinical development. Of these, 19 are at the Phase III testing or registration phases.

GSK also confirmed it expects five “major” new product approvals in 2025, including Blenrep (which tackles multiple myeloma) and Depemokimab (for severe asthma).

What next?

Investing in pharma shares like this can be dicey business at times. As GSK witnessed last year with Arexy, changes to the regulatory environment can cause havoc among certain product lines.

On top of this, developing medicines is highly complex and therefore unpredictable. Setbacks and the testing or registration phases can, through a blend of sales issues and extra costs, leave earnings forecasts in tatters.

But as today’s update shows, GSK’s making impressive strides even though these threats remain. Indeed, its strong record of pipeline execution remains highly encouraging, the business enjoying around a dozen positive late stage clinical updates in 2024 alone.

Its plans to become a powerhouse in the fields of respiratory, HIV and oncology treatments remain well on track.

Despite today’s rise, GSK’s shares still look cheap compared to those of its industry peers. Its forward price-to-earnings (P/E) ratio is a modest 10.2 times.

While nothing is guaranteed, I’m optimistic that GSK’s low valuation and impressive momentum could lead to more impressive share price gains. I think it’s a top FTSE 100 stock to consider.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Would Warren Buffett buy BP shares, as oil excitement grows?

Warren Buffett is a big investor in the oil business, and BP's performance has been attracting investor attention in results…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

Here’s how long-term loyalty to UK shares can lead to dazzling returns!

The most successful UK and US share investors buy shares to hold for the long term, as this report shows.

Read more »

Investing Articles

NatWest has just smashed brokers’ dividend forecasts!

After NatWest delivered a Valentine’s Day surprise to investors, our writer thinks the experts may have to raise their dividend…

Read more »

Investing Articles

The NatWest share price slips in early trading despite positive FY 2024 results. What’s the deal?

The NatWest share price is down slightly this morning after the bank released its final results for 2024. Our writer…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

My Legal & General shares have climbed just 7% — so how come I’m sitting on a 20% gain?

Harvey Jones' trading account is showing only a modest return on his Legal & General Shares, but on drilling down…

Read more »

Investing Articles

Prediction: the BP share price could rise in 2025 (or it might fall!)

Following this week’s release of the energy giant’s 2024 results, our writer reviews the prospects for the BP (LSE:BP.) share…

Read more »

many happy international football fans watching tv
Investing Articles

What’s gone wrong with the FTSE 100’s ‘King of Trainers’?

Feeling the pain of a 28% drop in the JD Sports share price over the past three months, our writer…

Read more »

Investing Articles

Is it too late for investors to consider buying these outstanding FTSE 100 shares?

Stephen Wright wonders whether now's the time to consider buying shares in the FTSE 100’s outstanding companies, despite some high…

Read more »